Biocon is currently trading at Rs. 347.35, up by 12.20 points or 3.64% from its previous closing of Rs. 335.15 on the BSE.
The scrip opened at Rs. 346.70 and has touched a high and low of Rs. 350.95 and Rs. 346.00 respectively. So far 49,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.15 on 19-Jul-2017 and a 52 week low of Rs. 267.57 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 350.95 and Rs. 329.10 respectively. The current market cap of the company is Rs. 20,949.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 18.80% and 20.53% respectively.
Biocon’s subsidiary in Malaysia, Biocon Sdn. Bhd., has been issued a certificate of GMP Compliance for its Insulin manufacturing facility by the HPRA (Ireland) as the representative European inspection authority. Biocon’s Malaysia facility was inspected by the EMA in April 2017.
The certificate of GMP compliance reflects that the agency considered the site to be in compliance with principles and guidelines of good manufacturing practices for active substances, sterile drug products and quality control testing operations.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
